[BIOLEX LOGO]
February 1, 2008
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Filing Desk
| Re: | Biolex Therapeutics, Inc. (formerly Biolex, Inc.) |
| Registration Statement on Form S-1 (Registration No. 333-145414) |
Ladies and Gentlemen:
Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Biolex Therapeutics, Inc. (formerly Biolex, Inc. and hereinafter, the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of its Registration Statement on Form S-1 (Registration No. 333-145414), together with all exhibits and amendments thereto (the “Registration Statement”). The Registrant is requesting such withdrawal because of unfavorable market conditions that would adversely affect the offering of the shares of common stock, par value $0.001 per share, covered by the Registration Statement. No securities were sold or will be sold under the Registration Statement. The Registration Statement has not been declared effective by the Commission.
The Registrant may undertake a subsequent private offering in reliance on Rule 155(c) under the Securities Act.
Please address any questions you may have to Jonathan L. Kravetz, Esq. and Brian P. Keane, Esq. at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, Massachusetts 02111, telephone numbers (617) 348-1674 and (617) 348-3093, facsimile number (617) 542-2241.
Thank you for your assistance with this matter.
| BIOLEX THERAPEUTICS, INC. | ||
| By: | /s/ Jan Turek | |
Jan Turek President and Chief Executive Officer | ||
| cc: | Securities and Exchange Commission |
| Division of Corporation Finance |
Jeffrey P. Riedler, Assistant Director
Sonia Barros, Esq.
| Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
Jonathan L. Kravetz, Esq.
Brian P. Keane, Esq.
| Pillsbury Winthrop Shaw Pittman LLP |
Todd W. Eckland, Esq.
David G. Odrich, Esq.
